ELFN1 and neoplasm: We examined the role of si‐ELFN1‐AS1 and ABT‐263 in combination therapy in vivo and observed that tumour volume and weight were significantly lower in the si‐ELFN1‐AS1 combined with ABT‐263 group (Figure 8A–C).